To Eden Biologics Investors, Partners, Colleagues and Friends:
I would like to take this opportunity to inform our shareholders that our CDMO Business Unit has been acquired by Bora Pharmaceuticals Co., LTD. Bora, effective as of July 1, 2022.
Eden Biologics, Inc., a leading global biotechnology company based in Hsinchu, Taiwan, announced on September 1st, the appointment of Dr. Steve Lee, an accomplished biotech executive with broad experience and entrepreneurial leadership, as the new CEO and Director of the Board, effective immediately.
We’ve once again achieved a huge corporate milestone and are excited to share the great news with all of you! Our EB-CLIN-1001-03 Phase 3 Clinical Trial for our leading Biosimilar Program EB1001, received approval from Hungary’s National Institute of Pharmacy and Nutrition (OGYÉI), as well as the Ethics Committee!
Earlier this week, the United States Department of Justice announced that it has filed criminal charges against Racho Jordanov and Rose Lin, former employees of JHL Biotech (the predecessor to Eden Biologics), relating to alleged theft of trade secrets from Genentech.
Eden Biologics is honored to announce the addition of Dr. Scott Liu as a member of the Eden Board of Directors.
Eden Biologics, Inc., a global frontrunner in biological drug development and manufacturing platform technologies, today announced completion of enrollment for their Phase 1 comparative PK Clinical Trial (JHL-CLIN-1266-01) of Eden’s lead product candidate EB1001
JHL Biotech, Inc., a global frontrunner in large-molecule biological drug development and manufacturing platform technologies, is excited to announce today that it has changed its corporate name to Eden Biologics, Inc.
Q-Sera Pty Ltd is pleased to announce a collaboration with JHL Biotech, Inc. (Taiwan) to produce high yielding recombinant ecarin for commercial scale production of RAPClot™ Rapid Serum tubes.
JHL Biotech, Inc. today announced that the first group of subjects has been randomized and dosed last week in the company’s Australian Phase I Clinical Trial of JHL1266 in healthy subjects.